Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

Long-acting lenacapavir has been shown to be a promising option for HIV PrEP and is now recommended globally by WHO, with a ...

An epidemic that's been sustained for 44 years might finally be quelled, with the milestone approval of the first HIV drug ...

DAP Health has received the new twice-yearly injection for HIV prevention. Here's what you need to know if you're interested ...

EMA recommends Gilead Sciences' Lenacapavir for HIV prevention, with FDA approval and generic options available soon.

Unfortunately, the Trump administration and the Republican majorities in Congress are putting access to lifesaving ...

Key points Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show striking effectiveness across diverse populations at high risk for HIV.

Gilead Sciences (NASDAQ:GILD) announced on Friday that the European Medicines Agency’s Committee for Medicinal Products for ...

The European Medicines Agency has recommended authorizing a twice-yearly injectable drug to prevent HIV. Scientists say this ...

WHO director general Tedros Adhanom Ghebreyesus says this new drug—which only needs to be injected twice a year—is the next ...

The World Health Organisation (WHO) released new guidelines recommending the use of injectable lenacapavir (LEN) twice a year ...

A breakthrough to reduce risk of HIV in adolescents and adults weighing at least 35 kg. WHO releases the new guidelines durings the world's most influential meeting on HIV research and its ...